Covidien Ltd. has received tentative FDA approval for the Abbreviated New Drug Application (ANDA) for its generic version of Cardiolite. The product, a Kit for the Preparation of Technetium Tc 99m Sestamibi Injection, is a myocardial perfusion imaging-agent that is designed for detecting coronary artery disease. The product would receive final approval once Cardiolite’s marketing exclusivity period expires on July 29.